Clinical trials: OAG - Open-Angle Glaucoma
Open-angle Glaucoma
Safety and Tolerability of a Prostaglandin Ocular Implant for Treatment of Open Angle Glaucoma
A single centre, open label, study to assess the safety, tolerability and biodegradation of PA5108 ocular implant in adults who have Open Angle Glaucoma (Primary or Secondary).
- Trial name
- NCT03604328
- Testing
- PA5108
- Where
- 2 sites in Australia
- Volunteers
- 8 people
- Sponsor
- PolyActiva Pty Ltd
Glaucoma Open-Angle Primary, Ocular Hypertension
Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
The trial will evaluate the safety and efficacy of 3 dose regimens of H-1337 [0.6% twice daily (b.i.d.), 1.0% b.i.d. and 1.0% once in the morning (q.a.m.), and timolol maleate (0.5%, b.i.d.) in both eyes for 28 days.
- Trial name
- NCT05913232
- Testing
- H-1337 0.6%, H-1337 1.0%, Timolol 0.5%
- Where
- 9 sites in United States
- Volunteers
- 201 people
- Sponsor
- D. Western Therapeutics Institute, Inc.
Normal Tension Glaucoma, Primary Open-angle Glaucoma
Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag Isopropyl
This study is for patients have been using prostaglandin analogue eye drops with a preservative for 3 months or more and have been diagnosed with prostaglandin-associated peri-orbital disease.
- Conditions
- Normal Tension Glaucoma, Primary Open-angle Glaucoma, Glaucoma, Suspect, Ocular Hypertension
- Trial name
- NOPAPS (NCT05279716)
- Testing
- Eybelis ophthalmic solution 0.002%
- Where
- 8 sites in South Korea
- Volunteers
- 150 people
- Sponsor
- Santen Pharmaceutical Asia Pte. Ltd.
Glaucoma, Open-Angle, Ocular Hypertension
Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution compared with bimatoprost ophthalmic solution (Lumigan®) as monotherapy and adjunctive therapy in patients with primary open-angle glaucoma or…
- Trial name
- NCT01291108
- Testing
- AGN-210669, bimatoprost, bimatoprost vehicle
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Allergan
Primary Open Angle Glaucoma
InnFocus MicroShunt Versus Trabeculectomy Study
Assess the safety and effectiveness of the InnFocus MicroShunt when used to lower intraocular pressure (IOP) in subjects with primary open angle glaucoma where the IOP is not controlled when using maximum tolerated glaucoma…
- Trial name
- IMS (NCT01881425)
- Testing
- Glaucoma Surgery, InnFocus MicroShunt
- Where
- 29 sites in United States, France and 4 more
- Volunteers
- 732 people
- Sponsor
- InnFocus Inc.
Primary Open Angle Glaucoma
Evaluation of the XEN Implant in Moderate Primary Open Angle Glaucoma (POAG) Participants
The objective of this study was to evaluate the AqueSys XEN Implant [XEN® Gel Stent (XEN45 Implant)] for the treatment of moderate primary open angle glaucoma (POAG) participants when medications have failed to control…
- Trial name
- NCT02006693
- Testing
- XEN® Gel Stent, Cataract Surgery
- Where
- 21 sites in Austria, Belgium and 7 more
- Volunteers
- 199 people
- Sponsor
- AqueSys, Inc.
Primary Open-angle Glaucoma
Safety and Effectiveness of VISULAS Green Selective Laser Trabeculoplasty (SLT)
An interventional, open, prospective, multi-center pre-market clinical investigation according to §§20-23a Medizinproduktegesetz (MPG, medical devices act), in which a total of 40 eyes of 40 consecutive patients at up to five (5)…
- Trial name
- NCT04519814
- Testing
- selective laser trabeculoplasty (SLT)
- Where
- 5 sites in Germany
- Volunteers
- 37 people
- Sponsor
- Carl Zeiss Meditec AG
Glaucoma, Open-Angle
Study of a Novel Interposition Supraciliary Implant in Patients With Open Angle Glaucoma
The purpose of this study is to evaluate the safety and effectiveness of a novel interposition supraciliary implant as a stand-alone therapy for lowering intraocular pressure (IOP) in patients with primary open angle glaucoma…
- Trial name
- SAFARI (NCT03736655)
- Testing
- Interposition supraciliary implant
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Ciliatech
Open-angle Glaucoma, Ocular Hypertension
A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to assess the comfort of a glaucoma therapy in patients with open-angle glaucoma or ocular hypertension
- Trial name
- NCT00326092
- Testing
- Brinzolamide/Timolol
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Alcon Research
Ocular Hypertension, Open-angle Glaucoma
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
A double-masked, parallel study of AR-12286 Ophthalmic Solution 0.5%, or 0.7% (q.d., PM) or timolol maleate Ophthalmic Solution, 0.5% (b.i.d.), O.U. for 3 months.
- Trial name
- NCT01699464
- Testing
- AR-12286 Ophthalmic Solution 0.7%, AR-12286 Ophthalmic Solution 0.5%, Timolol maleate ophthalmic solution 0.5%
- Volunteers
- 211 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma, Open-Angle, Ocular Hypertension
A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)
To compare the safety and IOP-lowering efficacy of TRAVATAN and XALCOM in subjects with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00051155
- Testing
- Travoprost (0.004%), Latanoprost (0.005%)/Timolol (0.5%)
- Where
- United States
- Sponsor
- Alcon Research
Primary Open-Angle Glaucoma, Ocular Hypertension
An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product
This study evaluates the long-term (13-months) safety of the Bimatoprost Ocular Insert in participants with Glaucoma or Ocular Hypertension who completed study FSV5-002.
- Trial name
- NCT02143843
- Testing
- Bimatoprost
- Where
- 10 sites in United States
- Volunteers
- 75 people
- Sponsor
- ForSight Vision5, Inc.
Open Angle Glaucoma, Ocular Hypertension
A Study to Investigate the Effect of IOP-lowering With TO-O-1001 Eye Drops in Healthy Subjects and in Patients With Open-Angle Glaucoma or Ocular Hypertension
This is a Phase I/II stage to investigate the safety, tolerability, and ocular hypotensive efficacy of TO-O-1001 in healthy volunteers and patients with Open-Angle Glaucoma or Ocular Hypertension.
- Trial name
- NCT05456724
- Testing
- TO-O-1001
- Where
- Australia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Theratocular Biotek Co.
Open Angle Glaucoma, Cataract
Safety of Hyaluronan Thiomer i.o. Implant During Combined Phacoemulsification - Non Penetrating Deep Sclerectomy
The study is designed to assess the safety of Hyaluronan Thiomer i.o. implant in patients with primary open angle glaucoma undergoing a combined phacoemulsification - non penetrating deep sclerectomy procedure.
- Trial name
- NCT01887873
- Testing
- Hyaluronan Thiomer i.o. implant
- Where
- Austria
- Volunteers
- 16 people
- Sponsor
- Croma-Pharma GmbH
Cataract, Glaucoma
High Frequency Deep Sclerotomy (HFDS) ab Interno a Combination Surgical Intervention Using Cataract Surgery to Lower IOP
Objective: To compare intraocular pressure lowering effect of combined sclerotomy ab interno with phacoemulsification and phacoemulsification alone, in primary or secondary open angle glaucoma patients.
- Conditions
- Cataract, Glaucoma, POAG
- Trial name
- HFDS_abinterno (NCT02312362)
- Testing
- Combined sclerotomy ab interno and phaco, Phacoemulsification with IOL implantation
- Where
- 5 sites in Egypt, Germany and 2 more
- Volunteers
- 108 people
- Sponsor
- Oertli Instrumente AG
Primary Open Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose
Primary objective: The primary objective is to demonstrate the superiority of Monoprost® versus Lumigan® 0.01% and Lumigan® 0.03% Unit Dose in term of safety with respect to the assessment of conjunctival hyperaemia in the worse…
- Trial name
- NCT02017327
- Testing
- Monoprost, Lumigan 0.01%, Lumigan 0.03% Unit Dose
- Where
- France
- Volunteers
- 379 people
- Sponsor
- Laboratoires Thea
Primary Open Angle Glaucoma (POAG)
Study of CyPass Implantation In Patients With Open Angle Glaucoma Refractory to Single or Multi-agent Topical Therapy
The purpose of this study is to evaluate the safety and effectiveness of CyPass implantation as a stand-alone therapy for lowering intraocular pressure (IOP) in patients with primary open angle glaucoma (POAG) who have failed at…
- Trial name
- DUETTE (NCT01166659)
- Testing
- CyPass Micro-Stent
- Volunteers
- 48 people
- Sponsor
- Transcend Medical, Inc.
Primary Open-Angle Glaucoma, Optic Nerve Injury
A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy
This is a randomized, double-masked, placebo-controlled Phase II clinical trial. The primary objective is to explore the efficacy of G01 Eye Drops in the treatment of optic nerve injury associated with open-angle glaucoma…
- Trial name
- NCT07777861
- Testing
- G01 Eye Drops 100μg/ml, G01 Eye Drops 200μg/ml
- Where
- 9 sites in China
- Volunteers
- 90 people
- Sponsor
- Qingdao WanMing BioCell Pharmaceutics Co.,Ltd.